Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

The Food and Drug Administration (FDA) has granted Qualified Disease Product and Fast Track designation to NRX-101 for the treatment of complicated urinary tract infection (cUTI) and pyelonephritis.

Pyelonephritis was suspected as the underlying cause of CKD in 6 of 22 cases. Pyelonephritis is an underrecognized cause of chronic kidney disease (CKD) in patients with orthotopic ileal neobladder ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

Cefepime-taniborbactam was 22% more effective than meropenem, which is a current treatment for complicated urinary tract infections (UTIs) and acute pyelonephritis, according to a study published in ...

New research suggests oral cephalosporins may be a safer alternative to fluoroquinolones for treating kidney infections like pyelonephritis.

March is National Kidney Month, a time to raise awareness about your kidney health and generate support for those affected by conditions, including kidney stones, kidney infections and kidney disease.

RADNOR, Pa., Jan. 16, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company ...

Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...